What is the best treatment for hypertension in African Americans?

Journal of Family Practice, Feb, 2007 by Shobha Rao, Manjula Cherukuri, Helen G. Mayo

EVIDENCE-BASED ANSWER

In African Americans with hypertension, therapy is best initiated with the low-sodium Dietary Approaches to Stop Hypertension (DASH) diet and a thiazidetype diuretic (strength of recommendation [SOR]: A, based on randomized controlled trials). If the blood pressure goal is not achieved with thiazide monotherapy, a calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker (ARB), or a beta-blocker can be added. An initial combination treatment is recommended for patients with systolic blood pressure >15 mm Hg or diastolic blood pressure >10 mm Hg above target (SOR: C, expert opinion).

African Americans have reduced blood pressure responses to monotherapy with beta-blocker, ACE inhibitor, or ARBs when compared to diuretics or calcium channel blockers (SOR: A, randomized controlled trials). However, cardiac and renal indications for prescribing these medications should be equally applied to African American patients (SOR: C, expert opinion).

CLINICAL COMMENTARY

African Americans respond better to combination ACE inhibitor plus diuretic Treat African American patients with hypertension according to the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC 7) guidelines. These guidelines state that patients with stage 1 hypertension, regardless of race, should be treated with lifestyle modification (to include a low-salt diet and weight loss) for 3 months. If, after a trial of lifestyle modification, these patients still have hypertension, then start diuretic therapy while continuing lifestyle modifications. If patients present with stage-2 hypertension, started them on a diuretic plus another agent. African American patients do not respond to ACE inhibitor monotherapy well, but do respond to the combination of an ACE inhibitor plus diuretic. If patients, regardless of race, have comorbid conditions that lend themselves to alternate antihypertensive treatment (ie, beta-blocker therapy post-myocardial infarction), then use these therapies first-line.

Mandi Sehgal, MD

University of Cincinnati

* Evidence summary

Three large cohort studies determined that African Americans have a higher prevalence of hypertension and worse cardiovascular and renal outcomes when compared with white Americans. For African American patients, the standard blood pressure goals apply: below 140/90 mm Hg with uncomplicated hypertension and below 130/80 with diabetes or renal disease. (1)

Dietary interventions

An RCT compared the effects of consuming the DASH diet (consisting of 4-5 servings of fruit, 4-5 servings of vegetables, 2-3 servings of low-fat dairy per day, and <25% fat) with a typical high-fat control diet among 459 adults with normal or elevated blood pressure. (2) Among 133 patients with hypertension, the DASH diet reduced systolic and diastolic blood pressure by 11.4 mm Hg (97.5% confidence interval [CI],-15.9 to -6.9) and 5.5 mm Hg (97.5% CI, -8.2 to -2.7) respectively when compared with the control diet. Among African Americans with hypertension, the DASH diet was even more beneficial, reducing their systolic and diastolic blood pressure by 13.2 mm Hg and 6.1 mm Hg respectively. (1)

Another RCT studied the effect of different levels of dietary sodium in conjunction with the DASH diet. (3) A total of 412 participants were randomly assigned to eat either a control diet or the DASH diet. Within the assigned diet, participants ate foods with high (150 mmol/d), intermediate (100 mmol/d), and low (50 mmol/d) levels of sodium in random order. In this study, low-sodium DASH diet was associated with additional lowering of blood pressure, an effect that was also found to be stronger for African Americans patients than others. (3) When compared with the combination of the control diet and a high level of sodium, the DASH diet and a low level of sodium lowered systolic blood pressure by 11.5 mm Hg for participants with hypertension (12.6 mm Hg for blacks; 9.5 mm Hg for others), and by 7.1 mm Hg for participants without hypertension (7.2 mm Hg for blacks; 6.9 mm Hg for others). (3)

Medical interventions

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (4) (ALLHAT) and African American Study of Kidney Disease and Hypertension (5) (AASK) have demonstrated the benefit of blood pressure reduction using specific classes of antihypertensive agents.

The ALLHAT trial, a double-blind RCT of 42,448 high-risk hypertensive patients aged >55 years, compared chlorthalidone (a thiazide-type diuretic) with amlodipine (Norvasc), lisinopril (Prinivil, Zestril), or doxazosin (Cardura). In this study, which included 36% African Americans, chlorthalidone, lisinopril, and amlodipine did not differ in preventing major cardiovascular events. However, lisinopril was associated with an increased risk for heart failure (relative risk [RR] for African Americans=1.32; 95% CI, 1.11-1.58) and stroke (RR for African Americans=l.4; 95% CI, 1.17-1.68), and amlodipine was associated with a higher risk of heart failure (RR in African Americans=l.47; 95% CI, 1.24-1.74). Additionally, ACE inhibitor-induced angioedema or cough occurred more frequently among African American patients than white patients. (4)

Although a randomized controlled trial (5) and a review of multiple studies(6) demonstrated that African Americans may be less responsive to monotherapy with ACE inhibitors, the AASK trial confirmed that ACE inhibitors can provide significant clinical benefits for African Americans with hypertensive renal disease. AASK, a double-blind RCT of 1094 African American patients with renal insufficiency, compared the effects of an ACE inhibitor (ramipril [Altace]), a dihydropyridine calcium channel blocker (amlodipine), or a beta blocker (metoprolol [Lopressor]) on the progression of hypertensive renal disease.